One more question:
Was Mr Dugar's meeting with CEO Eno in September or November 2017 to plan for "restructuring" BIOA's finances legal, and if they did meet -- one Conference was in Sarnia, so it defies imagination to assume they didn't meet after Eno was hired -- or was it legal to dump the other bidders?
In this context, why were two bidders listed and deleted on the same day, when the bidders were supposed to be secret? And what was the significance of Eno's purchase of 400K shares at the end of July. [Now I know there's been a debate about this. I personally saw a listing of the transaction. Or ... was that just a phantom purchase, and if so, why?]
By the way, I think Oracle placed a bid. Our DD guys said that contact during the bidding period only had to do with IT issues on site. But, judging from Oracle's Newsletter, Larry Ellison was clearly interested in pursuing entry into the BioChemical market. Consider the psychology of CEO competition ... over and above product diversity.
Come on, folks. $4.3M for all the patents and a facility that cost $40M. This is not Saturday Night Live.
